Management of Complications of CRS and HIPEC

摘要: The potential clinical benefits of cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) have for long been overshadowed by its relatively high morbidity mortality compared to other surgical procedures. It takes 3–12 months on an average the quality life return normal. With standardization indications, better patient selection, development implementation perioperative care pathways institution formal teaching programs, there has a reduction in overall from procedure, it is now similar that major gastrointestinal surgeries when performed specialized centres. Morbidity negative impact survival certain cancers (including colorectal cancer) can delay administration systemic therapy which equally important like ovarian cancer further emphasizes importance selection. may result significant additional financial burden where such procedures are not under ‘insurance cover’ ‘out-of-pocket’ spending patients. 90-day capture complication rate more accurately should be recorded reported instead 30-day mortality. Early recognition management complications multidisciplinary teams needed ‘rescue’ patients who develop complications.